Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data
Angeliki M Angelidi1, Emelina Stambolliu1,2, Konstantina I Adamopoulou1
1Society of Junior Doctors, Athens, Greece.
Background:
Current evidence indicates that statins increase the risk of new onset diabetes mellitus (NOD) and also deteriorate the glycemic control in patients with known diabetes mellitus (DM) after high-dose statin therapy.
Aims:
The aim of this review was to explore the effect of atorvastatin in causing NOD or deteriorating glycemic control in patients with DM.
Methods:
Two independent reviewers conducted the literature search, through PubMed database searching for articles published in English until April 2015, and only primary studies were included.
Results:
Of the 919 articles identified in our original search, 33 met the criteria for this review encompassing 1,951,113 participants. Twenty articles examined dysregulation of DM due to atorvastatin. Half of them showed that there was no significant change in glycemic control in patients treated with atorvastatin. Other studies showed that fasting plasma glucose and HbA1c levels were increased by atorvastatin. Thirteen articles examined if atorvastatin causes NOD. The majority of these articles showed that patients who used atorvastatin had a higher dose-dependent risk of developing NOD.
Conclusion:
This systematic review suggests that there is an association between atorvastatin treatment and NOD. Moreover, it showed that atorvastatin in high dose causes worsening of the glycemic control in patients with DM.
Insights
Atorvastatin use is linked to an increased risk of new onset diabetes mellitus (NOD). High-dose atorvastatin may also worsen glycemic control in patients with existing diabetes mellitus (DM).
Area of Science:
- Cardiovascular Pharmacology
- Endocrinology
- Metabolic Syndrome
Background:
- Statins are associated with increased risk of new onset diabetes mellitus (NOD).
- High-dose statin therapy can impair glycemic control in patients with diabetes mellitus (DM).
Purpose of the Study:
- To review the effects of atorvastatin on NOD development.
- To assess atorvastatin's impact on glycemic control in patients with DM.
Main Methods:
- Systematic literature search of PubMed for primary studies published until April 2015.
- Inclusion of 33 studies with 1,951,113 participants.
Main Results:
- Twenty studies examined atorvastatin's effect on DM; half found no significant glycemic changes, while others showed increased fasting plasma glucose and HbA1c.
- Thirteen studies investigated atorvastatin and NOD; most indicated a dose-dependent increased risk of NOD.
Conclusions:
- Atorvastatin treatment is associated with an increased risk of new onset diabetes mellitus (NOD).
- High-dose atorvastatin can lead to worsening glycemic control in patients with diabetes mellitus (DM).
Related Concept Videos
Mortar Joint Deterioration in Masonry
The...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Random and Systematic Errors
Systematic Sampling Method
Systematic sampling is one of the simplest methods...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...


